ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / RDY / financials
ELAN (45) BMRN (74) SMMT (40) SYRE (55) ⌘ Pro Terminal →

Dr. Reddy's Laboratories Ltd (RDY) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$14.13 -0.28% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $14.10

Dr. Reddy's Laboratories Ltd (RDY) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $11.83B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RDY Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RDY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Dr. Reddy's Laboratories Ltd (NYSE: RDY) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $14.13 (-0.28% 1D, market cap $11.83B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, RDY ranks #126 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RDY compare to ELAN and BMRN in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RDY carries a Roarable C (64/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, ELAN (Elanco Animal Health Incorporated) holds a D grade (45/100 RQD, P/E N/A, ROIC -2.5%, cap $11.52B) and BMRN (BioMarin Pharmaceutical Inc.) posts a B grade (74/100 RQD, P/E 31.9x, ROIC 6.0%, cap $11.33B). Among the 5-stock peer group, BMRN leads on earnings multiple (31.9x) while RDY leads on capital efficiency (9.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RDY?
▼

For Dr. Reddy's Laboratories Ltd (RDY), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs and sector rank #126 in Health Care, while primary risk factors center on Broader market pullbacks can still drag down strong stocks in the short run and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $14.10 (-0.24%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 6.5% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 64/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.1% avg 90D alpha vs SPY • 55.2% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C
025507510064
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C- · Rk B-
Cash (11)Whales (13)SEC (16)Macro (12)CEO (12)
Each axis scored 0–20
12M PRICE TARGET CONE+2.7% Base Target
$17 Bull$15 Base$11 Bear
📬 FREE RDY RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RDY)Realized 20D OHLCV Swing Band: ±3.6%
Deterministic 5-Pillar Attribution (64/100 Composite)
🔍 WHY RDY SCORES 64/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (25% of score)

Altman Z-Score 3.74 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Whale & Options Positioning+13/20 pts (20% of score)

20D Institutional Volume Accumulation (±3.6% realized swing band)

▼ #1 Drag / Risk Factor: Cash Engine Quality11/20 pts (-9 pt drag)

Capital intensity & 13.9% operating margin leave 9 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
56
Grade C$12.75+3.5% Next Q
Q2 (-2Q)
59
Grade C$13.19+7.3% Next Q
Q3 (-1Q)
61
Grade C$14.15-0.1% Next Q
Current
64
Grade C$14.13+1.1% Hist 90D α
Trajectory: C (56) → C (64)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the RDY Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 64/100 (C) score, RDY faces multiple-compression risk if 32.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($12.65) or 200D SMA ($13.23) invalidates the momentum regime and cuts Target Base ($14.51) toward Bear Floor ($11.32).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RDY• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RDY Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 64%NO 36%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • Trailing 12 Months

How RDY Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$261.4M (6.5% FCF Margin)
Revenue$4.00BGross Profit $2.08B (52%)Cost of Sales $1.92BOp Profit $556.0M (13.9%)OpEx (R&D/SG&A) $1.52BNet Profit$436.0M (10.9%)Tax/Other $120.0M
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RDY)

  • ✓Walkthrough of RDY's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
RDY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +5.84%⚡ TESTING RESISTANCE
2026-11-03O $14.11H $14.17L $14.11C $14.13VOL 1.83M
RES: $14.27SUP: $11.65SMA50: $12.65SMA200: $13.23
$15.97$14.72$13.47$12.22$10.97RES $14.27SUP $11.65$14.132026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RDY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RDY Butterfly Map → + Track RDY →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
25.3%/yr Implied 5Y Growth

vs. +6.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on RDY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RDY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RDY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RDY)

Health Care Rank #126 of 1015 ⚔️ ELAN vs RDY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RDY vs. ELAN, BMRN, SMMT, SYRE)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Dr. Reddy's Laboratories Ltd (RDY) ranks #126 by composite RQD confidence (64/100, grade C) and #92 by equity capitalization ($11.83B). Within this direct 5-issuer industry benchmark cohort, BMRN leads on earnings valuation at 31.9x trailing P/E, while RDY leads on capital efficiency and profitability with 9.9% ROIC and — gross margin. BMRN currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with RDY at 64/100 (C).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
RDY ACTIVE
Dr. Reddy's Laboratories Ltd
C 64/100 32.8x — 9.9% -0.28% $11.83B Benchmark Subject
ELAN
Elanco Animal Health Incorporated
D 45/100 — 55.0% -2.5% +4.51% $11.52B /elan-vs-rdy →
BMRN
BioMarin Pharmaceutical Inc.
B 74/100 31.9x 77.7% 6.0% -1.83% $11.33B /bmrn-vs-rdy →
SMMT
Summit Therapeutics Inc.
D- 40/100 — — -35.0% -7.67% $12.82B /smmt-vs-rdy →
SYRE
Spyre Therapeutics Inc.
D+ 55/100 — — -20.0% -1.09% $10.08B /syre-vs-rdy →

2. RDY Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Dr. Reddy's Laboratories Ltd (RDY) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $11.83B, trailing P/E of 32.8x, forward P/E of 30.5x, and EV/EBITDA of 21.0x. Operating profitability registers a gross margin of —, operating margin of 13.9%, net profit margin of 10.9%, ROIC of 9.9%, and free cash flow yield of 2.21%, alongside an Altman Z-Score of 3.74 and Piotroski F-Score of 8/9.

3. RDY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RDY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Dr. Reddy's Laboratories Ltd (NYSE: RDY) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $14.13 (-0.28% 1D, market cap $11.83B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, RDY ranks #126 in composite RQD confidence.

How does RDY compare to ELAN and BMRN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RDY carries a Roarable C (64/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, ELAN (Elanco Animal Health Incorporated) holds a D grade (45/100 RQD, P/E N/A, ROIC -2.5%, cap $11.52B) and BMRN (BioMarin Pharmaceutical Inc.) posts a B grade (74/100 RQD, P/E 31.9x, ROIC 6.0%, cap $11.33B). Among the 5-stock peer group, BMRN leads on earnings multiple (31.9x) while RDY leads on capital efficiency (9.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RDY?

For Dr. Reddy's Laboratories Ltd (RDY), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs and sector rank #126 in Health Care, while primary risk factors center on Broader market pullbacks can still drag down strong stocks in the short run and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RDY trading relative to its 50-day, 200-day, and 52-week technical levels?

RDY last traded at $14.13 (-0.28% on volume of 1,932,026 shares), positioning the stock +11.70% above its 50-day simple moving average ($12.65) and +6.80% above its 200-day simple moving average ($13.23). Across its 52-week range of $11.36 to $15.67, RDY sits at the 64.3% percentile with a 14-day RSI of 76.2 (OVERBOUGHT (>70)) and an implied next-earnings move of ±3.6% ($13.62 to $14.64).

Direct Sub-Reports: RDY RQD Cockpit RDY 12M Forecast RDY Earnings & Move RDY Dividends & DRIP RDY Insiders & 13F RDY Whale Options RDY Profit Sankey RDY News & Why
ROARABLE RATING BRIEF • RQD 64/100 (C) ✓ SEC XBRL & RQD VERIFIED

RDY — Dr. Reddy's Laboratories Ltd: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Dr. Reddy's Laboratories Ltd (RDY) earns a live Roarable RQD composite score of 64/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $14.13 (-0.28% 1D, market capitalization $11.83B).

  • Fundamental Cash Engine (11/20): Anchored by return on invested capital (ROIC) of 9.9%, gross margin of —, operating margin of 13.9%, and free cash flow yield of 2.21%.
  • Whale 13F & Options Flow (13/20) + Insider Conviction (12/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (12/20) + Forensic Balance Sheet (16/20): Incorporates a 1.05x equity beta, Altman Z-Score of 3.74, Piotroski F-Score of 8/9, and Debt/Equity of 0.39x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Dr. Reddy's Laboratories Ltd is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry,. Per the market data, the company reports an operating margin of 13.9% and a net margin of 10.9%.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C • RQD 64/100): Clean SEC annual filing review with no major hidden accounting time-bombs. Free cash flow yield of 2.21% and institutional whale pillar of 13/20. With Fundamental Cash Engine at 11/20 and Institutional Whale Flow at 13/20, sustained execution supports upside toward the upper end of the $11.36 – $15.67 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 32.8x trailing P/E and 21.0x EV/EBITDA against 13.9% operating margins and a 1.05x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream dependencies, sector correlations, or proprietary signals are recorded.

From a sector-analysis standpoint only: pharmaceutical preparation companies are commonly exposed to regulatory decisions, drug pricing, and generic competition, but none of these exposures are documented for RDY in the source data. Investors should treat these as open questions rather than established risks for this issuer.

  • Key Question #1: Can RDY sustain or expand its 13.9% operating margin and 9.9% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (2.21% FCF yield) strengthen balance-sheet liquidity (Altman Z-Score 3.74) toward the $15.67 52-week high?
  • Key Question #3: How sensitive is RDY's 30.5x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.05x)?

RDY Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Dr. Reddy's Laboratories Ltd (RDY) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RDY Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RDY Bull vs. Bear Conversation Board — What's Your Call at $14.13?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RDY 🐻 33% BEARISH CONVICTION
1. Pick Your Side on RDY:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $18.56 (+31.0%)
📌 Pinned Debate

Per the Roarable RQD rating, the Forensic Balance Sheet pillar scores 16/20 with Altman Z 3.74, Piotroski F 8/9, and Debt/Equity 0.39,

Don't sleep on RDY's setup in Health Care. Per the Roarable RQD rating, the Forensic Balance Sheet pillar scores 16/20 with Altman Z 3.74, Piotroski F 8/9, and Debt/Equity 0.39, indicating financial strength.. Beta of 1.05 means it moves fast when momentum turns, and the 5-pillar RQD gauge (64/100) backs up the fundamental quality.

ArenaChamp_24 🐂 BULL

@DeepValue_CFA Agree on the RQD 64/100 quality, though with 1.05 beta I'm scaling in with half-size at $14.17 and keeping dry powder in case we test $13.18.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $11.90 (-16.0%)
Spot @ $14.17

Per the market data, a P/E (TTM) of 32.8 and FCF yield of 2.21% indicate a demanding valuation relative to current cash generation.

Sitting on the sidelines or leaning short RDY above $14.17. Per the market data, a P/E (TTM) of 32.8 and FCF yield of 2.21% indicate a demanding valuation relative to current cash generation.. Until Fundamental Cash Engine (11/20) and FCF yield (2.21%) inflect higher, upside is capped near $15.67.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%